224 related articles for article (PubMed ID: 1324641)
1. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
2. Herpes and human ribonucleotide reductases. Inhibition by 2-acetylpyridine 5-[(2-chloroanilino)-thiocarbonyl]-thiocarbonohydrazone (348U87).
Spector T; Harrington JA; Porter DJ
Biochem Pharmacol; 1991 Jun; 42(1):91-6. PubMed ID: 1648925
[TBL] [Abstract][Full Text] [Related]
3. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.
Spector T; Harrington JA; Morrison RW; Lambe CU; Nelson DJ; Averett DR; Biron K; Furman PA
Proc Natl Acad Sci U S A; 1989 Feb; 86(3):1051-5. PubMed ID: 2536930
[TBL] [Abstract][Full Text] [Related]
4. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Lobe DC; Spector T; Ellis MN
Antiviral Res; 1991 Feb; 15(2):87-100. PubMed ID: 1650166
[TBL] [Abstract][Full Text] [Related]
5. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
6. Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
Safrin S; Schacker T; Delehanty J; Hill E; Corey L
Antimicrob Agents Chemother; 1993 May; 37(5):975-9. PubMed ID: 8390815
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.
Spector T; Averett DR; Nelson DJ; Lambe CU; Morrison RW; St Clair MH; Furman PA
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4254-7. PubMed ID: 2987969
[TBL] [Abstract][Full Text] [Related]
8. Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.
Ellis MN; Lobe DC; Spector T
Antimicrob Agents Chemother; 1989 Oct; 33(10):1691-6. PubMed ID: 2556074
[TBL] [Abstract][Full Text] [Related]
9. 2-Acetylpyridine thiocarbonohydrazones. Potent inactivators of herpes simplex virus ribonucleotide reductase.
Blumenkopf TA; Harrington JA; Koble CS; Bankston DD; Morrison RW; Bigham EC; Styles VL; Spector T
J Med Chem; 1992 Jun; 35(12):2306-14. PubMed ID: 1319497
[TBL] [Abstract][Full Text] [Related]
10. The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture.
Lawetz C; Liuzzi M
Antiviral Res; 1998 Jul; 39(1):35-46. PubMed ID: 9754948
[TBL] [Abstract][Full Text] [Related]
11. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
[TBL] [Abstract][Full Text] [Related]
12. Ribonucleotide reductase induced by varicella zoster virus. Characterization, and potentiation of acyclovir by its inhibition.
Spector T; Stonehuerner JG; Biron KK; Averett DR
Biochem Pharmacol; 1987 Dec; 36(24):4341-6. PubMed ID: 2825724
[TBL] [Abstract][Full Text] [Related]
13. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
14. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.
Ellis MN; Keller PM; Fyfe JA; Martin JL; Rooney JF; Straus SE; Lehrman SN; Barry DW
Antimicrob Agents Chemother; 1987 Jul; 31(7):1117-25. PubMed ID: 2821890
[TBL] [Abstract][Full Text] [Related]
15. Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Safrin S; Schacker T; Delehanty J; Hill E; Corey L
J Med Virol; 1993; Suppl 1():146-9. PubMed ID: 8245882
[TBL] [Abstract][Full Text] [Related]
16. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus type 1 ribonucleotide reductase: selective and synergistic inactivation by A1110U and its iron complex.
Porter DJ; Harrington JA; Spector T
Biochem Pharmacol; 1990 Feb; 39(4):639-46. PubMed ID: 2154988
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.
Coen DM; Goldstein DJ; Weller SK
Antimicrob Agents Chemother; 1989 Aug; 33(8):1395-9. PubMed ID: 2552912
[TBL] [Abstract][Full Text] [Related]
19. Effects of acyclovir, oxetanocin-G, and carbocyclic oxetanocin-G in combinations on the replications of herpes simplex virus type 1 and type 2 in Vero cells.
Saijo M; Suzutani T; Yoshida I
Tohoku J Exp Med; 1992 May; 167(1):57-68. PubMed ID: 1333651
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan.
Hasegawa T; Kawana T; Okuda T; Horii M; Tsukada T; Shiraki K
J Med Virol; 2001 Jan; 63(1):57-63. PubMed ID: 11130888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
